Table 1.
Baseline Characteristics of Study Participants
| Gender, N (%) | Male | 51 (71.8) |
| Female | 20 (28.2) | |
| Age at start anlotinib (years) | Average±SD | 68± 9 |
| Tobacco, N (%) | Never smoker | 26 (36.6) |
| Current smoker | 38 (53.5) | |
| Former smoker | 7 (9.9) | |
| ECOG PS, N (%) | 0 | 49 (69.0) |
| 1 | 22 (31.0) | |
| Histologic type, N (%) | Squamous cell carcinoma | 14 (57.7) |
| Adenocarcinoma | 49 (69.0) | |
| Small cell lung cancer | 7 (9.9) | |
| Other | 1 (1.4) | |
| Metastasis sites, N (%) | Brain | 8 (11.3) |
| Liver | 2 (2.8) | |
| Bone | 20 (28.2) | |
| No | 7 (9.9) | |
| Lymphatic metastasis | Yes | 61 (85.9) |
| No | 10 (14.1) | |
| Number of metastatic sites, N (%) | ≤ 1 | 59 (83.1) |
| > 1 | 12 (16.9) | |
| Clinical stage, N (%) | IIIA-IIIB | 15 (21.1) |
| IV | 56 (78.9) | |
| Gene mutation, N (%) | EGFR mutation | 7 (9.9) |
| Wild type | 64 (90.1) | |
| Prior lines of therapy, N (%) | ≤ 3 | 43 (60.6) |
| > 3 | 28 (39.4) | |
| Previous therapy, N (%) | Chemotherapy | 54 (76.0) |
| Radiation therapy | 18 (25.4) | |
| Targeted treatment | 27 (38.0) | |
| PD–1 inhibitor | 1 (1.4) | |
| CRP, mg/La | Median (IQR) | 12.0 (3.0–48.3) |
| ANC (×109/L) | Median (IQR) | 4.6 (3.7–6.3) |
| ALC (×109/L) | Median (IQR) | 1.3 (0.9–1.7) |
Note: aData were missing in three patients.
Abbreviations: EGFR, epidermal growth factor receptor; PD-1, programmed cell death protein-1; CRP, C–reactive protein; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; SD, standard deviation; IQR, interquartile range.